Forge Biologics joins California-backed program to support production of AAV gene therapies

Forge Biologics, a genetic medicines manufacturing specialist, joined a California-backed organization that aims to boost the development of adeno-associated adenovirus (AAV) gene therapies.

The state of California has pumped $5.5 billion into the California Institute for Regenerative Medicine (CIRM), which funds clinical trials for cell and gene therapies among other therapeutic modalities.

For its part, Forge joined the CIRM's Industry Resource Partner Program. The company will help CIRM's partners as they work through various stages of gene therapy development and potentially commercialization.

Forge is capable of working with AAV gene therapy programs at any stage, the company said in a release. All of its manufacturing operations run out of Forge's 200,000-square-foot facility in Columbus, Ohio.

Forge was founded in 2020 and the following year hauled in $120 million in funding.

In May, the company signed a manufacturing deal to help Life Biosciences advance its gene therapy platform for age-related diseases.

As for CIRM, some of its other partners include Novo Nordisk and Bayer, according to the group's website.